Liposomes in drug delivery

Fundamentals and Applications of Controlled Release Drug Delivery

Volumn , Issue , 2012, Pages 289-328

  Torchilin, Vladimir ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; DIAGNOSTIC PRODUCTS; DRUG PRODUCTS; LIPOSOMES; PHOSPHOLIPIDS;

BILAYERED; CURRENT STATUS; DIAGNOSTIC AGENTS; DRUG DELIVERY SYSTEM; PHARMACEUTICAL CARRIERS; RELATED PRODUCTS; THERANOSTICS;

TARGETED DRUG DELIVERY;

EID: 84969427161     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-0881-9_11     Document Type: Chapter

References (335)

1. Abra RM, Bankert RB, Chen F, Egilmez NK, Huang K, Saville R, Slater JL, Sugano M, Yokota SJ (2002) The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res 12:1-3
2. Adamo V, Lorusso V, Rossello R, Adamo B, Ferraro G, Lorusso D, Condemi G, Priolo D, Di Lullo L, Paglia A, Pisconti S, Scambia G, Ferrandina G (2008) Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. Br J Cancer 98:1916-1921
3. Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, Monsky WL, Torchilin VP, Goldberg SN (2005) Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 235:469-477
4. Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN (2005) Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol 16:1365-1371
5. Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133-141
6. Allen TM, Mumbengegwi DR, Charrois GJ (2005) Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 11:3567-3573
7. Allison AG, Gregoriadis G (1974) Liposomes as immunological adjuvants. Nature 252:252
8. Asokan A, Cho MJ (2003) Cytosolic delivery of macromolecules. II. Mechanistic studies with pH-sensitive morpholine lipids. Biochim Biophys Acta 1611:151-160
9. Atobe K, Ishida T, Ishida E, Hashimoto K, Kobayashi H, Yasuda J, Aoki T, Obata K, Kikuchi H, Akita H, Asai T, Harashima H, Oku N, Kiwada H (2007) In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1- MMP). Biol Pharm Bull 30:972-978
10. Audouy SA, de Leij LF, Hoekstra D, Molema G (2002) In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 19:1599-1605
11. Awasthi VD, Garcia D, Klipper R, Goins BA, Phillips WT (2004) Neutral and anionic liposome-encapsulated hemoglobin: effect of postinserted poly(ethylene glycol)-distearoyl- phosphatidylethanolamine on distribution and circulation kinetics. J Pharmacol Exp Ther 309:241-248
12. Babincova M, Altanerova V, Lampert M, Altaner C, Machova E, Sramka M, Babinec P (2000) Site-specific in vivo targeting of magnetoliposomes using externally applied magnetic field. Z Naturforsch C 55:278-281
13. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, Sherwood RF (1988) A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58:700-703
14. Balbi G, Visconti S, Monteverde A, Manganaro MA, Cardone A (2007) Liposomal doxorubicin: a phase II trial. Acta Biomed 78:210-213
15. Bao A, Goins B, Klipper R, Negrete G, Mahindaratne M, Phillips WT (2003) A novel liposome radiolabeling method using 99mTc-"SNS/S" complexes: in vitro and in vivo evaluation. J Pharm Sci 92:1893-1904
16. Bao A, Goins B, Klipper R, Negrete G, Phillips WT (2003) 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 44:1992-1999
17. Bendsoe N, Persson L, Johansson A, Axelsson J, Svensson J, Grafe S, Trebst T, Andersson- Engels S, Svanberg S, Svanberg K (2007) Fluorescence monitoring of a topically applied liposomal Temoporfin formulation and photodynamic therapy of nonpigmented skin malignancies. J Environ Pathol Toxicol Oncol 26:117-126
18. Benesch M, Urban C (2008) Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 9:301-309
19. Blume G, Cevc G (1993) Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Biophys Acta 1146:157-168
20. Blume G, Cevc G, Crommelin MD, Bakker-Woudenberg IA, Kluft C, Storm G (1993) Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta 1149:180-184
21. Boddapati SV, D'Souza GG, Erdogan S, Torchilin VP, Weissig V (2008) Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett 8:2559-2563
22. Boddapati SV, Tongcharoensirikul P, Hanson RN, D'Souza GG, Torchilin VP, Weissig V (2005) Mitochondriotropic liposomes. J Liposome Res 15:49-58
23. Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MV, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ, Nanus DM (2007) Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J Immunother 30:655-662
24. Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN (2002) Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 50:6-8
25. Bourre L, Thibaut S, Fimiani M, Ferrand Y, Simonneaux G, Patrice T (2003) In vivo photosensitizing efficiency of a diphenylchlorin sensitizer: interest of a DMPC liposome formulation. Pharmacol Res 47:253-261
26. Brignole C, Pagnan G, Marimpietri D, Cosimo E, Allen TM, Ponzoni M, Pastorino F (2003) Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett 197:231-235
27. Budai L, Hajdu M, Budai M, Grof P, Beni S, Noszal B, Klebovich I, Antal I (2007) Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int J Pharm 343:34-40
28. Cevc G (2004) Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 56:675-711
29. Cevc G, Blume G (2001) New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochim Biophys Acta 1514:191-205
30. Cevc G, Gebauer D (2003) Hydration-driven transport of deformable lipid vesicles through fine pores and the skin barrier. Biophys J 84:1010-1024
31. Cevc G, Schatzlein A, Richardsen H (2002) Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta 1564:21-30
32. Chen B, Pogue BW, Hasan T (2005) Liposomal delivery of photosensitising agents. Expert Opin Drug Deliv 2:477-487
33. Cheng WW, Allen TM (2008) Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release 126:50-58
34. Cheng WW, Das D, Suresh M, Allen TM (2007) Expression and purification of two anti- CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim Biophys Acta 1768:21-29
35. Chikh G, Schutze-Redelmeier MP (2002) Liposomal delivery of CTL epitopes to dendritic cells. Biosci Rep 22:339-353
36. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP (2001) Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 167:6462-6470
37. Colley CM, Ryman BE (1976) The use of a liposomally entrapped enzyme in the treatment of an artificial storage condition. Biochim Biophys Acta 451:417-425
38. Connor J, Huang L (1986) pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res 46:3431-3435
39. Cooley T, Henry D, Tonda M, Sun S, O'Connell M, Rackoff W (2007) A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist 12:114-123
40. Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, Tyler PC, Davies NM (2003) Liposomal delivery of antigen to human dendritic cells. Vaccine 21:883-890
41. Crommelin DJ, Storm G (2003) Liposomes: from the bench to the bed. J Liposome Res 13:33-36
42. D'Souza GG, Wang T, Rockwell K, Torchilin VP (2008) Surface modification of pharmaceutical nanocarriers with ascorbate residues improves their tumor-cell association and killing and the cytotoxic action ofencapsulated paclitaxel in vitro. Pharm Res 25:2567-2572
43. Dagar S, Rubinstein I, Onyuksel H (2003) Liposomes in ultrasound and gamma scintigraphic imaging. Methods Enzymol 373:198-214
44. Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA (2005) Randomized trial of two intravenous schedules of the topoisomer- ase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 23:1859-1866
45. Deonarain MP, Epenetos AA (1994) Targeting enzymes for cancer therapy: old enzymes in new roles. Br J Cancer 70:786-794
46. Derycke AS, De Witte PA (2002) Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. Int J Oncol 20:181-187
47. Derycke AS, de Witte PA (2004) Liposomes for photodynamic therapy. Adv Drug Deliv Rev 56:17-30
48. Desai TR, Hancock RE, Finlay WH (2002) A facile method of delivery of liposomes by nebulization. J Control Release 84:69-78
49. Desnick RJ, Thorpe SR, Fiddler MB (1976) Toward enzyme therapy for lysosomal storage diseases. Physiol Rev 56:57-99
50. Diebold Y, Jarrin M, Saez V, Carvalho EL, Orea M, Calonge M, Seijo B, Alonso MJ (2007) Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 28:1553-1564
51. Ding WX, Qi XR, Fu Q, Piao HS (2007) Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. Drug Deliv 14:101-104
52. Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A (2006) A phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol 58:759-764
53. Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, Bur M, Poff J, Xie J, Libutti SK, Li KC, Wood BJ (2007) Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 13:2722-2727
54. du Plessis J, Egbaria K, Ramachandran C, Weiner N (1992) Topical delivery of liposomally encapsulated gamma-interferon. Antiviral Res 18:259-265
55. Egbaria K, Ramachandran C, Kittayanond D, Weiner N (1990) Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies. Antimicrob Agents Chemother 34:107-110
56. Egbaria K, Ramachandran C, Weiner N (1990) Topical delivery of ciclosporin: evaluation of various formulations using in vitro diffusion studies in hairless mouse skin. Skin Pharmacol 3:21-28
57. el Guink N, Kris RM, Goodman-Snitkoff G, Small PA Jr, Mannino RJ (1989) Intranasal immunization with proteoliposomes protects against influenza. Vaccine 7:147-151
58. Elbayoumi TA, Torchilin VP (2006) Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging 33:1196-1205
59. Elbayoumi TA, Torchilin VP (2007) Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci 32:159-168
60. Elbayoumi TA, Torchilin VP (2008) Liposomes for targeted delivery of antithrombotic drugs. Expert Opin Drug Deliv 5:1185-1198
61. Elbayoumi TA, Torchilin VP (2008) Tumor-specific antibody-mediated targeted delivery of Doxil((R)) reduces the manifestation of auricular erythema side effect in mice. Int J Pharm 357:272-279
62. Elbayoumi TA, Torchilin VP (2009) Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol Pharm 6:246-254
63. ElBayoumi TA, Torchilin VP (2009) Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer- specific monoclonal antibody. Clin Cancer Res 15:1973-1980
64. Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM (2006) Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm 322:60-66
65. Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM (2007) Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen. Pharmazie 62:133-137
66. Erdogan S, Medarova ZO, Roby A, Moore A, Torchilin VP (2008) Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. J Magn Reson Imaging 27:574-580
67. Erdogan S, Roby A, Sawant R, Hurley J, Torchilin VP (2006) Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes. J Liposome Res 16:45-55
68. Erdogan S, Roby A, Torchilin VP (2006) Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes. Mol Pharm 3:525-530
69. Fattal E, Couvreur P, Dubernet C (2004) "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev 56:931-946
70. Felgner PL, Ringold GM (1989) Cationic liposome-mediated transfection. Nature 337:387-388
71. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890-896
72. Fishman Y, Citri N (1975) L-asparaginase entrapped in liposomes: preparation and properties. FEBS Lett 60:17-20
73. Fleisher D, Niemiec SM, Oh CK, Hu Z, Ramachandran C, Weiner N (1995) Topical delivery of growth hormone releasing peptide using liposomal systems: an in vitro study using hairless mouse skin. Life Sci 57:1293-1297
74. Fonseca MJ, Jagtenberg JC, Haisma HJ, Storm G (2003) Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. Pharm Res 20:423-428
75. Freeman BA, Turrens JF, Mirza Z, Crapo JD, Young SL (1985) Modulation of oxidant lung injury by using liposome-entrapped superoxide dismutase and catalase. Fed Proc 44:2591-2595
76. Freeman BA, Young SL, Crapo JD (1983) Liposome-mediated augmentation of superoxide dismutase in endothelial cells prevents oxygen injury. J Biol Chem 258:12534-12542
77. Friede M (1995) Liposomes as carriers of antigens. In: Philippot JR, Schuber F (eds) Liposomes as tools in basic research and industry. CRC, Boca Raton, pp 189-200
78. Fujimoto Y, Okuhata Y, Tyngi S, Namba Y, Oku N (2000) Magnetic resonance lymphography of profundus lymph nodes with liposomal gadolinium-diethylenetriamine pentaacetic acid. Biol Pharm Bull 23:97-100
79. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S (2004) Tumor cell targeting of liposome- entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177-1192
80. Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424-436
81. Gijsens A, Derycke A, Missiaen L, De Vos D, Huwyler J, Eberle A, de Witte P (2002) Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int J Cancer 101:78-85
82. Gilbert BE, Seryshev A, Knight V, Brayton C (2002) 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhal Toxicol 14:185-197
83. Goncalves A, Braud AC, Viret F, Genre D, Gravis G, Tarpin C, Giovannini M, Maraninchi D, Viens P (2003) Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors. Anticancer Res 23:3543-3548
84. Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO (2006) Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 16:521-526
85. Gorodetsky R, Levdansky L, Vexler A, Shimeliovich I, Kassis I, Ben-Moshe M, Magdassi S, Marx G (2004) Liposome transduction into cells enhanced by haptotactic peptides (Haptides) homologous to fibrinogen C-termini. J Control Release 95:477-488
86. Grabowsky GA, Desnick RJ (1981) Enzyme replacement in genetic diseases. In: Holcenberg JS, Roberts J (eds) Enzymes as drugs. Wiley, New York, p 167
87. Grant GJ, Barenholz Y, Bolotin EM, Bansinath M, Turndorf H, Piskoun B, Davidson EM (2004) A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology 101:133-137
88. Gregoriadis G (1978) Liposomes in the therapy of lysosomal storage diseases. Nature 275:695-696
89. Gregoriadis G (1993) Liposomes as immunological adjuvants for peptide and protein antigens. In: Gregoriadis G, Florence AT, Patel HM (eds) Liposomes in drug delivery. Harwood Academic Publishers, Switzerland, pp 77-94
90. Gregoriadis G (2007) Liposome technology: Liposome preparation and related techniques, 3rd edn., 1-3. Informa Healthcare, New York, p 1240
91. Gregoriadis G, Dean MF (1979) Enzyme therapy in genetic diseases. Nature 278:603-604
92. Gregoriadis G, Putman D, Louis L, Neerunjun D (1974) Comparative effect and fate of non- entrapped and liposome-entrapped neuraminidase injected into rats. Biochem J 140:323-330
93. Gregoriadis G, Ryman BE (1972) Lysosomal localization of -ffuctofuranosidase-containing liposomes injected into rats. Biochem J 129:123-133
94. Griffiths GD, Phillips GJ, Bailey SC (1999) Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation. Vaccine 17:2562-2568
95. Groll AH, Mickiene D, Petraitis V, Petraitiene R, Alfaro RM, King C, Piscitelli SC, Walsh TJ (2003) Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits. Antimicrob Agents Chemother 47:3917-3925
96. Guan HH, Budzynski W, Koganty RR, Krantz MJ, Reddish MA, Rogers JA, Longenecker BM, Samuel J (1998) Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 9:451-458
97. Gupta B, Levchenko TS, Torchilin VP (2007) TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res 16:351-359
98. Gupta B, Torchilin VP (2007) Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother 56:1215-1223
99. Gupta Y, Jain A, Jain P, Jain SK (2007) Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J Drug Target 15:231-240
100. Han YY, Huang L, Jackson EK, Dubey RK, Gillepsie DG, Carcillo JA (2001) Liposomal atp or NAD+ protects human endothelial cells from energy failure in a cell culture model of sepsis. Res Commun Mol Pathol Pharmacol 110:107-116
101. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM (1995) Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1239:133-144
102. Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, Stewart JS (2001) Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 37:2015-2022
103. Hartner WC, Verma DD, Levchenko TS, Bernstein EA, Torchilin VP (2009) ATP-loaded liposomes for treatment of myocardial ischemia. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:530-539
104. Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, Yasuda J, Obata K, Kikuchi H, Ishida T, Kiwada H, Harashima H (2007) Tumor targeting of doxorubicin by anti- MT1-MMP antibody-modified PEG liposomes. Int J Pharm 342:194-200
105. Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H (2004) Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm 281:25-33
106. Hathout RM, Mansour S, Mortada ND, Guinedi AS (2007) Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech 8:1
107. Hayward JA, Levine DM, Neufeld L, Simon SR, Johnston DS, Chapman D (1985) Polymerized liposomes as stable oxygen-carriers. FEBS Lett 187:261-266
108. Heath TD, Shek P, Papahadjopoulos D (1986) Production of immunogens by antigen conjugation to liposomes. The Regents of the University of California, United States
109. Heeremans JL, Prevost R, Bekkers ME, Los P, Emeis JJ, Kluft C, Crommelin DJ (1995) Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Thromb Haemost 73:488-494
110. Honeywell-Nguyen PL, Frederik PM, Bomans PHH, Junginger HE, Bouwstra JA (2002) Transdermal delivery of pergolide from surfactant-based elastic and rigid vesicles: characterization and in vitro transport studies. Pharmaceut Res (NY) 19:991-997
111. Hudson LD, Fiddler MB, Desnick RJ (1979) Enzyme therapy. X. Immune response induced by enzyme- and buffer-loaded liposomes in C3H/HeJ Gus(h) mice. J Pharmacol Exp Ther 208:507-514
112. Huwyler J, Wu D, Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164-14169
113. Ichikawa K, Takeuchi Y, Yonezawa S, Hikita T, Kurohane K, Namba Y, Oku N (2004) Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth. Cancer Lett 205:39-48
114. Igarashi A, Konno H, Tanaka T, Nakamura S, Sadzuka Y, Hirano T, Fujise Y (2003) Liposomal photofrin enhances therapeutic efficacy of photodynamic therapy against the human gastric cancer. Toxicol Lett 145:133-141
115. Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, Johkura K, Yonemura Y (2002) Intracellular targeting therapy of cisplatin-encapsulated transferrinpolyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 99:130-137
116. Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, Eriguchi M, Yanagie H (2001) Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res 18:1042-1048
117. Iwanaga K, Ono S, Narioka K, Kakemi M, Morimoto K, Yamashita S, Namba Y, Oku N (1999) Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J Pharm Sci 88:248-252
118. Jayanna PK, Torchilin VP, Petrenko VA (2009) Liposomes targeted by fusion phage proteins. Nanomedicine 5:83-89
119. Jehn CF, Boulikas T, Kourvetaris A, Possinger K, Luftner D (2007) Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res 27:471-475
120. Jezek P, Nekvasil M, Skobisova E, Urbankova E, Jirsa M, Zadinova M, Pouckova P, Klepacek I (2003) Experimental photodynamic therapy with MESO-tetrakisphenylporphyrin (TPP) in liposomes leads to disintegration of human amelanotic melanoma implanted to nude mice. Int J Cancer 103:693-702
121. Johnston SR, Gore ME (2001) Caelyx: phase II studies in ovarian cancer. Eur J Cancer 37 (Suppl 9):S8-S14
122. Jorge JC, Perez-Soler R, Morais JG, Cruz ME (1994) Liposomal palmitoyl-L-asparaginase: characterization and biological activity. Cancer Chemother Pharmacol 34:230-234
123. Joshee N, Bastola DR, Cheng PW (2002) Transferrin-facilitated lipofection gene delivery strategy: characterization of the transfection complexes and intracellular trafficking. Hum GeneTher 13:1991-2004
124. Kakudo T, Chaki S, Futaki S, Nakase I, Akaji K, Kawakami T, Maruyama K, Kamiya H, Harashima H (2004) Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 43:5618-5628
125. Kale AA, Torchilin VP (2007) Design, synthesis, and characterization of pH-sensitive PEG- PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the pH stability of PEG-PE conjugates. Bioconjug Chem 18:363-370
126. Kale AA, Torchilin VP (2007) Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target 15:538-545
127. Kamps JA, Koning GA, Velinova MJ, Morselt HW, Wilkens M, Gorter A, Donga J, Scherphof GL (2000) Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer. J Drug Target 8:235-245
128. Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K (2001) A novel and simple type of liposome carrier for recombinant interleukin-2. J Pharm Pharmacol 53:295-302
129. Karanth H, Murthy RS (2007) pH-sensitive liposomes-principle and application in cancer therapy. J Pharm Pharmacol 59:469-483
130. Kato A, Tanaka I, Arakawa M, Kondo T (1985) Liposome-type artificial red blood cells stabilized with carboxymethyl chitin. Biomater Med Devices Artif Organs 13:61-82
131. Kedar E, Palgi O, Golod G, Babai I, Barenholz Y (1997) Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. J Immunother 20:180-193
132. Kessner S, Krause A, Rothe U, Bendas G (2001) Investigation of the cellular uptake of E-Selectin-targeted immunoliposomes by activated human endothelial cells. Biochim Biophys Acta 1514:177-190
133. Khaw BA, daSilva J, Vural I, Narula J, Torchilin VP (2001) Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. J Control Release 75:199-210
134. Khaw BA, Torchilin VP, Vural I, Narula J (1995) Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat Med 1:1195-1198
135. Kheirolomoom A, Dayton PA, Lum AF, Little E, Paoli EE, Zheng H, Ferrara KW (2007) Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle. J Control Release 118:275-284
136. Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, Cantos C, Scherman D, Jorgensen C, Apparailly F (2006) Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 54:1867-1877
137. Kim CK, Han JH (1995) Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. J Microencapsul 12:437-446
138. Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK, Herbst RS (2001) A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 34:427-432
139. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36:66-75
140. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732-6740
141. Kisel MA, Kulik LN, Tsybovsky IS, Vlasov AP, Vorob'yov MS, Kholodova EA, Zabarovskaya ZV (2001) Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm 216:105-114
142. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N (1995) Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 18:93-99
143. Klibanov AL, Maruyama K, Torchilin VP, Huang L (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268:235-237
144. Klibanov AL, Torchilin VP, Zalipsky S (2003) Long-circulating sterically protected liposomes. In: Torchilin VP, Weissig V (eds) Liposomes: a practical approach, 2nd edn. Oxford University Press, New York, pp 231-265
145. Konduri KS, Nandedkar S, Duzgunes N, Suzara V, Artwohl J, Bunte R, Gangadharam PR (2003) Efficacy of liposomal budesonide in experimental asthma. J Allergy Clin Immunol 111:321-327
146. Koning GA, Gorter A, Scherphof GL, Kamps JA (1999) Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells. Br J Cancer 80:1718-1725
147. Konno H, Matin AF, Maruo Y, Nakamura S, Baba S (1996) Liposomal ATP protects the liver from injury during shock. Eur Surg Res 28:140-145
148. Koshkina NV, Golunski E, Roberts LE, Gilbert BE, Knight V (2004) Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 17:7-14
149. Koshkina NV, Kleinerman ES, Waidrep C, Jia SF, Worth LL, Gilbert BE, Knight V (2000) 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6:2876-2880
150. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T (2001) Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int J Oncol 18:121-125
151. Laham A, Claperon N, Durussel JJ, Fattal E, Delattre J, Puisieux F, Couvreur P, Rossignol P (1988) Liposomally entrapped adenosine triphosphate. Improved efficiency against experimental brain ischaemia in the rat. J Chromatogr 440:455-458
152. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK (2006) Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 5:1708-1713
153. Lange CF, Hancock RE, Samuel J, Finlay WH (2001) In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J Pharm Sci 90:1647-1657
154. Lanternier F, Lortholary O (2008) Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect 14(Suppl 4):71-83
155. Lasic DD, Martin FJ (1995) Stealth liposomes. CRC, Boca Raton, p 320
156. Lasic DD, Papahadjopoulos D (1998) Medical applications of liposomes. Elsevier, Amsterdam, p xiv, 79
157. Lasic DD, Vallner JJ, Working PK (1999) Sterically stabilized liposomes in cancer therapy and gene delivery. Curr Opin Mol Ther 1:177-185
158. Law SL, Shih CL (2001) Characterization of calcitonin-containing liposome formulations for intranasal delivery. J Microencapsul 18:211-221
159. Leamon CP, Cooper SR, Hardee GE (2003) Folate-liposome-mediated antisense oligodeox- ynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem 14:738-747
160. Leamon CP, Low PS (1991) Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA 88:5572-5576
161. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M (2002) Novel chondroitin sulfate-binding cationic liposomes loaded with cis- platin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 62:4282-4288
162. Lee RJ, Low PS (1994) Delivery of liposomes into cultured KB cells via folate receptor- mediated endocytosis. J Biol Chem 269:3198-3204
163. Li H, Song JH, Park JS, Han K (2003) Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int J Pharm 258:11-19
164. Liang W, Levchenko T, Khaw BA, Torchilin V (2004) ATP-containing immunoliposomes specific for cardiac myosin. Curr Drug Deliv 1:1-7
165. Lo YL, Tsai JC, Kuo JH (2004) Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase. J Control Release 94:259-272
166. Lokling KE, Fossheim SL, Klaveness J, Skurtveit R (2004) Biodistribution of pH-responsive liposomes for MRI and a novel approach to improve the pH-responsiveness. J Control Release 98:87-95
167. Lopes de Menezes DE, Pilarski LM, Allen TM (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320-3330
168. Lopes de Menezes DE, Pilarski LM, Belch AR, Allen TM (2000) Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta 1466:205-220
169. Lu Y, Low PS (2002) Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54:675-693
170. Lu Y, Low PS (2002) Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 51:153-162
171. Ludewig B, Barchiesi F, Pericin M, Zinkemagel RM, Hengartner H, Schwendener RA (2000) In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine 19:23-32
172. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP (2004) Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 100:135-144
173. Lundberg BB, Griffiths G, Hansen HJ (2007) Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody. Drug Deliv 14:171-175
174. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS (1985) Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 817:67-74
175. Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47-61
176. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW (2003) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 63:3154-3161
177. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65:11631-11638
178. Mamot C, Ritschard R, Kung W, Park JW, Herrmann R, Rochlitz CF (2006) EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J Drug Target 14:215-223
179. Manesis EK, Cameron CH, Gregoriadis G (1979) Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen. FEBS Lett 102:107-111
180. Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, Schwendener RA (2002) Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer 87:106-112
181. Maruyama K (2000) In vivo targeting by liposomes. Biol Pharm Bull 23:791-799
182. Mastrobattista E, Koning GA, van Bloois L, Filipe AC, Jiskoot W, Storm G (2002) Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem 277:27135-27143
183. Masuda K, Horie K, Suzuki R, Yoshikawa T, Hirano K (2002) Oral delivery of antigens in liposomes with some lipid compositions modulates oral tolerance to the antigens. Microbiol Immunol 46:55-58
184. Matsuura M, Yamazaki Y, Sugiyama M, Kondo M, Ori H, Nango M, Oku N (2003) Polycation liposome-mediated gene transfer in vivo. Biochim Biophys Acta 1612:136-143
185. Metselaar JM, Bruin P, de Boer LW, de Vringer T, Snel C, Oussoren C, Wauben MH, Crommelin DJ, Storm G, Hennink WE (2003) A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem 14:1156-1164
186. Minato S, Iwanaga K, Kakemi M, Yamashita S, Oku N (2003) Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J Control Release 89:189-197
187. Moein Moghimi S, Hamad I, Bunger R, Andresen TL, Jorgensen K, Hunter AC, Baranji L, Rosivall L, Szebeni J (2006) Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J Liposome Res 16:167-174
188. Moghimi SM, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42:463-478
189. Nam SM, Kim HS, Ahn WS, Park YS (1999) Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells. Oncol Res 11:9-16
190. Naoi M, Yagi K (1980) Incorporation of enzyme through blood-brainbarrier into the brain by means of liposomes. Biochem Int 1:591-596
191. Neveux N, De Bandt JP, Chaumeil JC, Cynober L (2002) Hepatic preservation, liposomally entrapped adenosine triphosphate and nitric oxide production: a study of energy state and protein metabolism in the cold-stored rat liver. Scand J Gastroenterol 37:1057-1063
192. Ni S, Stephenson SM, Lee RJ (2002) Folate receptor targeted delivery of liposomal daunoru- bicin into tumor cells. Anticancer Res 22:2131-2135
193. Niibori K, Wroblewski KP, Yokoyama H, Crestanello JA, Whitman GJ (1999) Bioenergetic effect of liposomal coenzyme Q10 on myocardial ischemia reperfusion injury. Biofactors 9:307-313
194. Nobuto H, Sugita T, Kubo T, Shimose S, Yasunaga Y, Murakami T, Ochi M (2004) Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int J Cancer 109:627-635
195. O'Shaughnessy JA (2003) Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 4:318-328
196. Omori N, Maruyama K, Jin G, Li F, Wang SJ, Hamakawa Y, Sato K, Nagano I, Shoji M, Abe K (2003) Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol Res 25:275-279
197. Opanasopit P, Sakai M, Nishikawa M, Kawakami S, Yamashita F, Hashida M (2002) Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. J Control Release 80:283-294
198. Oussoren C, Storm G (2001) Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 50:143-156
199. Pagnan G, Montaldo PG, Pastorino F, Raffaghello L, Kirchmeier M, Allen TM, Ponzoni M (1999) GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer 81:268-274
200. Pan H, Han L, Chen W, Yao M, Lu W (2008) Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J Control Release 125:228-235
201. Pan XQ, Wang H, Lee RJ (2003) Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 20:417-422
202. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ (2002) Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100:594-602
203. Pappalardo JS, Quattrocchi V, Langellotti C, Di Giacomo S, Gnazzo V, Olivera V, Calamante G, Zamorano PI, Levchenko TS, Torchilin VP (2009) Improved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes. J Control Release 134:41-46
204. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172-1181
205. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC (2001) Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95-113
206. Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M (2003) Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 63:86-92
207. Patel HM, Ryman BE (1974) a-Mannosidase in zinc-deficient rats. Possibility of liposomal therapy in mannosidosis. Biochem Soc Trans 2:1014-1017
208. Patel NR, Hatziantoniou S, Georgopoulos A, Demetzos C, Torchilin VP, Weissig V, D'Souza GG (2010) Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J Liposome Res 20(3):244-249
209. Peer D, Margalit R (2004) Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 108:780-789
210. Perez-Lopez ME, Curiel T, Gomez JG, Jorge M (2007) Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 18:611-617
211. Perez AT, Domenech GH, Frankel C, Vogel CL (2002) Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest 20(Suppl 2):22-29
212. Phillips WT, Klipper RW, Awasthi VD, Rudolph AS, Cliff R, Kwasiborski V, Goins BA (1999) Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. J Pharmacol Exp Ther 288:665-670
213. Plassat V, Martina MS, Barratt G, Menager C, Lesieur S (2007) Sterically stabilized superparamagnetic liposomes for MR imaging and cancer therapy: pharmacokinetics and biodistribution. Int J Pharm 344:118-127
214. Postma NS, Crommelin DJ, Eling WM, Zuidema J (1999) Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice. J Pharmacol Exp Ther 288:114-120
215. Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, Bogenmann E, Ponzoni M, Montaldo PG (2003) Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Lett 197:151-155
216. Rao M, Alving CR (2000) Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. Adv Drug Deliv Rev 41:171-188
217. Reddy JA, Abburi C, Hofland H, Howard SJ, Vlahov I, Wils P, Leamon CP (2002) Folate- targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther 9:1542-1550
218. Reynolds GC, Baker HJ, Reynolds RH (1978) Enzyme replacement using liposome carriers in feline Gm1 gangliosidosis fibroblasts. Nature 275:754-755
219. Rogers JA, Anderson KE (1998) The potential of liposomes in oral drug delivery. Crit Rev Ther Drug Carrier Syst 15:421-480
220. Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA (2004) Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc 126:9506-9507
221. Roux E, Passirani C, Scheffold S, Benoit JP, Leroux JC (2004) Serum-stable and long- circulating, PEGylated, pH-sensitive liposomes. J Control Release 94:447-451
222. Ruozi B, Battini R, Montanari M, Mucci A, Tosi G, Forni F, Vandelli MA (2007) DOTAP/ UDCA vesicles: novel approach in oligonucleotide delivery. Nanomedicine 3:1-13
223. Sachse A, Leike JU, Rossling GL, Wagner SE, Krause W (1993) Preparation and evaluation of lyophilized iopromide-carrying liposomes for liver tumor detection. Invest Radiol 28:838-844
224. Sachse A, Leike JU, Schneider T, Wagner SE, Rossling GL, Krause W, Brandl M (1997) Biodistribution and computed tomography blood-pool imaging properties of polyethylene glycol-coated iopromide-carrying liposomes. Invest Radiol 32:44-50
225. Safinya CR (2001) Structures of lipid-DNA complexes: supramolecular assembly and gene delivery. Curr Opin Struct Biol 11:440-448
226. Sakai H, Masada Y, Horinouchi H, Yamamoto M, Ikeda E, Takeoka S, Kobayashi K, Tsuchida E (2004) Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. Crit Care Med 32:539-545
227. Sakai H, Tomiyama KI, Sou K, Takeoka S, Tsuchida E (2000) Poly(ethylene glycol- conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state. Bioconjug Chem 11:425-432
228. Sakai H, Tsai AG, Rohlfs RJ, Hara H, Takeoka S, Tsuchida E, Intaglietta M (1999) Microvascular responses to hemodilution with Hb vesicles as red blood cell substitutes: influence of O2 affinity. Am J Physiol 276:H553-H562
229. Sanchez Y, Ionescu-Matiu I, Dreesman GR, Kramp W, Six HR, Hollinger FB, Melnick JL (1980) Humoral and cellular immunity to hepatitis B virus-derived antigens: comparative activity of Freund complete adjuvant alum, and liposomes. Infect Immun 30:728-733
230. Sangha R, Butts C (2007) L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 13:s4652-s4654
231. Sapra P, Allen TM (2002) Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 62:7190-7194
232. Sapra P, Allen TM (2004) Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 10:2530-2537
233. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F (2000) Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 11:69-72
234. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M (2007) Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28:1434-1442
235. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP (2006) "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 17:943-949
236. Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Storm G (2003) Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91:115-122
237. Schmidinger M, Wenzel C, Locker GJ, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky AC (2001) Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 85:1850-1852
238. Schnyder A, Krahenbuhl S, Drewe J, Huwyler J (2005) Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J Drug Target 13:325-335
239. Schroeder A, Avnir Y, Weisman S, Najajreh Y, Gabizon A, Talmon Y, Kost J, Barenholz Y (2007) Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir 23:4019-4025
240. Schwonzen M, Kurbacher CM, Mallmann P (2000) Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 11:681-685
241. Scott RC, Wang B, Nallamothu R, Pattillo CB, Perez-Liz G, Issekutz A, Valle LD, Wood GC, Kiani MF (2007) Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol Bioeng 96:795-802
242. Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, Sivret J, Rusk J, Barrett E (2004) A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 93:229-232
243. Selzman CH, Shames BD, Reznikov LL, Miller SA, Meng X, Barton HA, Werman A, Harken AH, Dinarello CA, Banerjee A (1999) Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. Circ Res 84:867-875
244. Senior JH (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 3:123-193
245. Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellstrom I, Hellstrom KE (1988) Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 85:4842-4846
246. Shibuya-Fujiwara N, Hirayama F, Ogata Y, Ikeda H, Ikebuchi K (2001) Phagocytosis in vitro of polyethylene glycol-modified liposome-encapsulated hemoglobin by human peripheral blood monocytes plus macrophages through scavenger receptors. Life Sci 70:291-300
247. Simoes S, Moreira JN, Fonseca C, Duzgunes N, de Lima MC (2004) On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 56:947-965
248. Sinha RK, Khuller GK (1997) The protective efficacy of a liposomal encapsulated 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra against tuberculosis in mice. Immunol Cell Biol 75:461-466
249. Sioud M, Sorensen DR (2003) Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 312:1220-1225
250. Skubitz KM (2003) Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 21:167-176
251. Sofou S (2007) Surface-active liposomes for targeted cancer therapy. Nanomed 2:711-724
252. Sofou S, Sgouros G (2008) Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv 5:189-204
253. Stanimirovic DB, Markovic M, Micic DV, Spatz M, Mrsulja BB (1994) Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion 'oxidative stress' in gerbil brain. Neurochem Res 19:1473-1478
254. Steele G Jr, Ravikumar T, Ross D, King V, Wilson RE, Dodson T (1984) Specific active immunotherapy with butanol-extracted, tumor-associated antigens incorporated into liposomes. Surgery 96:352-359
255. Steger LD, Desnick RJ (1977) Enzyme therapy. VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. Biochim Biophys Acta 464:530-546
256. Stephenson SM, Yang W, Stevens PJ, Tjarks W, Barth RF, Lee RJ (2003) Folate receptor- targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Antican- cerRes 23:3341-3345
257. Storm G, Vingerhoeds MH, Crommelin DJA, Haisma HJ (1997) Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs. Adv Drug Del Rev 24:225-231, 227
258. Sudimack JJ, Guo W, Tjarks W, Lee RJ (2002) A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta 1564:31-37
259. Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB (2000) Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 60:6942-6949
260. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R (2003) Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37:800-804
261. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86:72-78
262. Szebeni J, Alving CR (1999) Complement-mediated acute effects of liposome-encapsulated hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 27:23-41
263. Szebeni J, Di Iorio EE, Hauser H, Winterhalter KH (1985) Encapsulation of hemoglobin in phospholipid liposomes: characterization and stability. Biochemistry 24:2827-2832
264. Szebeni J, Fontana JL, Wassef NM, MonganPD, Morse DS, Dobbins DE, Stahl GL, BungerR, Alving CR (1999) Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99:2302-2309
265. Szoka F Jr, Papahadjopoulos D (1980) Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 9:467-508
266. Taira MC, Chiaramoni NS, Pecuch KM, Alonso-Romanowski S (2004) Stability of liposomal formulations in physiological conditions for oral drug delivery. Drug Deliv 11:123-128
267. Takeuchi H, Kojima H, Yamamoto H, Kawashima Y (2001) Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release 75:83-91
268. Takeuchi H, Yamamoto H, Kawashima Y (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47:39-54
269. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y (1996) Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res 13:896-901
270. Takeuchi Y, Ichikawa K, Yonezawa S, Kurohane K, Koishi T, Nango M, Namba Y, Oku N (2004) Intracellular target for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome. J Control Release 97:231-240
271. Tan PH, Manunta M, Ardjomand N, Xue SA, Larkin DF, Haskard DO, Taylor KM, George AJ (2003) Antibody targeted gene transfer to endothelium. J Gene Med 5:311-323
272. Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, Harvie P, Bermudes D, Mayer L (2009) In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 33:129-139
273. Templeton NS (2002) Cationic liposome-mediated gene delivery in vivo. Biosci Rep 22:283-295
274. Terada T, Mizobata M, Kawakami S, Yamashita F, Hashida M (2007) Optimization of tumor- selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. J Control Release 119:262-270
275. Tilcock C (1995) Imaging tools: liposomal agents for nuclear medicine, computed tomography, magnetic resonance, and ultrasound. In: Philippot JR, Schuber F (eds) Liposomes as tools in basic research and industry. CRC, Boca Raton, pp 225-240
276. Torchilin V (2008) Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 5:1003-1025
277. Torchilin VP (1985) Liposomes as targetable drug carriers. Crit Rev Ther Drug Carrier Syst 2:65-115
278. Torchilin VP (1996) Liposomes as delivery agents for medical imaging. Mol Med Today 2:242-249
279. Torchilin VP (1997) Surface-modified liposomes in gamma- and MR-imaging. Adv Drug Deliv Rev 24:301-313
280. Torchilin VP (2000) Polymeric contrast agents for medical imaging. Curr Pharm Biotechnol 1:183-215
281. Torchilin VP (2005) Liposomal delivery of protein and peptide drugs. In: Mahato RI (ed) Biomaterials for delivery and targeting of proteins and nucleic acids, chapter 14. CRC, Boca Raton, pp 433-459
282. Torchilin VP, Klibanov AL, Huang L, O'Donnell S, Nossiff ND, Khaw BA (1992) Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J 6:2716-2719
283. Torchilin VP, Levchenko TS (2003) TAT-liposomes: a novel intracellular drug carrier. Curr Protein Pept Sci 4:133-140
284. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, Samokhin GP, Whiteman KR (2001) p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta 1511:397-411
285. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Stemberg B, D'Souza GG (2003) Cell transfection in vitro and in vivo with nontoxic TAT peptide- liposome-DNA complexes. Proc Natl Acad Sci USA 100:1972-1977
286. Torchilin VP, Levchenko TS, Whiteman KR, Yaroslavov AA, Tsatsakis AM, Rizos AK, Michailova EV, Shtilman MI (2001) Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials 22:3035-3044
287. Torchilin VP, Rammohan R, Weissig V, Levchenko TS (2001) TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 98:8786-8791
288. Torchilin VP, Trubetskoy VS (1995) Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev 16:141-155
289. Torchilin VP, Weissig V (2003) Liposomes: a practical approach. Practical approach series; 264, 2nd edn. Oxford University Press, New York, p xxiii
290. Torchilin VP, Weissig V, Martin FJ, Heath TD, Ne RRC (2003) Surface modifications of liposomes. In: Torchilin VP, Weissig V (eds) Liposomes: a practical approach, 2nd edn. Oxford University Press, New York, pp 193-229
291. Trudel M, Nadon F (1981) Virosome preparation: differences between influenza and rubella hemagglutinin adsorption. Can J Microbiol 27:958-962
292. Tseng YL, Hong RL, Tao MH, Chang FH (1999) Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer 80:723-730
293. Tseng YL, Liu JJ, Hong RL (2002) Translocation of liposomes into cancer cells by cell- penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol 62:864-872
294. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E (2006) Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M D. Anderson Cancer Center Series. Leuk Lymphoma 47:1062-1068
295. Tsuchida E, Hasegawa E, Matsushita Y, Eshima K, Yuasa M, Nishide H (1985) Polymerized liposome as the carrier of heme. A physically stable oxygen carrier under physiological conditions. Chem Lett 13:969-972
296. Tuffin G, Waelti E, Huwyler J, Hammer C, Marti HP (2005) Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J Am Soc Nephrol 16:3295-3305
297. Turk MJ, Reddy JA, Chmielewski JA, Low PS (2002) Characterization of a novel pH- sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim Biophys Acta 1559:56-68
298. Umezawa F, Eto Y, Tokoro T, Ito F, Maekawa K (1985) Enzyme replacement with liposomes containing beta-galactosidase from Charonia lumpas in murine globoid cell leukodystrophy (twitcher). Biochem Biophys Res Commun 127:663-667
299. van Winden EC (2003) Freeze-drying of liposomes: theory and practice. Methods Enzymol 367:99-110
300. Verma DD, Hartner WC, Levchenko TS, Bernstein EA, Torchilin VP (2005) ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res 22:2115-2120
301. Verma DD, Hartner WC, Thakkar V, Levchenko TS, Torchilin VP (2007) Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res 24(11):2131-2137
302. Verma DD, Levchenk T, Bernstein EA, Torchilin V (2004) ATP-loaded liposomes effectively protect mechanical functions of the myocardium from global ischemia in an isolated rat heart model. In: 31st annual meeting of the Controlled Release Society, Honolulu 2004, Controlled Release Society, #572
303. Verma DD, Levchenko TS, Bernstein EA, Mongayt D, Torchilin VP (2006) ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model. J Drug Target 14:273-280
304. Verma DD, Verma S, Blume G, Fahr A (2003) Liposomes increase skin penetration of entrapped and non-entrapped hydrophilic substances into human skin: a skin penetration and confocal laser scanning microscopy study. Eur J Pharm Biopharm 55:271-277
305. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW (2004) In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med 51:1153-1162
306. Vingerhoeds MH, Haisma HJ, Belliot SO, Smit RH, Crommelin DJ, Storm G (1996) Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharm Res 13:604-610
307. Vutla NB, Betageri GV, Banga AK (1996) Transdermal iontophoretic delivery of enkephalin formulated in liposomes. J Pharm Sci 85:5-8
308. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P (2004) Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 269:37-49
309. Wadia JS, Stan RV, Dowdy SF (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10:310-315
310. Weissig VV, Babich J, Torchilin VV (2000) Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool. Colloids Surf B Biointerfaces 18:293-299
311. Westcott KR, Hill RL (1985) Reconstitution of a porcine submaxillary gland beta-D-galac- toside alpha 2-3 sialyltransferase into liposomes. J Biol Chem 260:13116-13121
312. Whiteman KR, Subr V, Ulbrich K, Torchilin VP (2001) Poly(HPMA)-coated liposomes demonstrate prolonged circulation in mice. J Liposome Res 11:153-164
313. Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, Knopf B, Koch HJ, Hauschild A (2003) Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:993-1001
314. Woodle MC (1998) Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev 32:139-152
315. Woodle MC, Storm G (1998) Long circulating liposomes: old drugs, new therapeutics. Biotechnology intelligence unit. Springer, Berlin, 301 p
316. Wu ZH, Ping QN, Wei Y, Lai JM (2004) Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice. Acta Pharmacol Sin 25:966-972
317. Xu GX, Xie XH, Liu FY, Zang DL, Zheng DS, Huang DJ, Huang MX (1990) Adenosine triphosphate liposomes: encapsulation and distribution studies. Pharm Res 7:553-557
318. Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM, Pirollo KF, Chang EH (2002) Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv- immunoliposomes. Mol Cancer Ther 1:337-346
319. Yagi N, Naoi M, Sasaki H, Abe H, Konishi H, Arichi S (1982) Incorporation of enzyme into the brain by means of liposomes of novel composition. J Appl Biochem 4:121-125
320. Yamabe K, Kato Y, Onishi H, Machida Y (2003) Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. J Control Release 89:429-436
321. Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD (2007) Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120:169-177
322. Yang T, Cui FD, Choi MK, Lin H, Chung SJ, Shim CK, Kim DD (2007) Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv 14:301-308
323. Yang TZ, Wang XT, Yan XY, Zhang Q (2002) Phospholipid deformable vesicles for buccal delivery of insulin. Chem Pharm Bull (Tokyo) 50:749-753
324. Yerushalmi N, Arad A, Margalit R (1994) Molecular and cellular studies of hyaluronic acid- modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch Biochem Biophys 313:267-273
325. Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JL (2001) Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 7:1237-1245
326. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356
327. Zajac-Kaye M, Ts'o PO (1984) DNAase I encapsulated in liposomes can induce neoplastic transformation of Syrian hamster embryo cells in culture. Cell 39:427-437
328. Zalipsky S, Qazen M, Walker JA 2nd, Mullah N, Quinn YP, Huang SK (1999) New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem 10:703-707
329. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG (2007) Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm 67:655-666
330. Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP (2006) siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 112:229-239
331. Zheng J, Liu J, Dunne M, Jaffray DA, Allen C (2007) In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm Res 24:1193-1201
332. Zheng J, Liu J, Dunne M, Jaffray DA, Allen C (2007) In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm Res 24:1193-1201
333. Zheng J, Perkins G, Kirilova A, Allen C, Jaffray DA (2006) Multimodal contrast agent for combined computed tomography and magnetic resonance imaging applications. Invest Radiol 41:339-348
334. Zhong ZR, Liu J, Deng Y, Zhang ZR, Song QG, Wei YX, He Q (2007) Preparation and characterization of a novel nonviral gene transfer system: procationic-liposome-protamine- DNA complexes. Drug Deliv 14:177-183
335. Zhou F, Kraehenbuhl JP, Neutra MR (1995) Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes. Vaccine 13:637-644